| ²é¿´: 1002 | »Ø¸´: 0 | |||||||||||||
18408211912гæ (³õÈëÎÄ̳)
|
[½»Á÷]
ÖÐÄÏ´óÑ§ÏæÑÅÒ½Ôº·Ö×Ó´úл×éѧÖÐÐÄ³ÏÆ¸ »ùÓÚ´úл×éѧ¼¼ÊõµÄרְ¿ÆÑÐÈËÔ±/²©Ê¿ºó/¼¼ÊõÔ
|
ÖÐÄÏ´óÑ§ÏæÑÅÒ½Ôº·Ö×Ó´úл×éѧÖÐÐÄ³ÏÆ¸ »ùÓÚ´úл×éѧ¼¼ÊõµÄרְ¿ÆÑÐÈËÔ±/²©Ê¿ºó/¼¼ÊõÔ± ÖÐÄÏ´óÑ§ÏæÑÅÒ½Ôº·Ö×Ó´úл×éѧÑо¿ÖÐÐÄʼ½¨ÓÚ 2017 Ä꣬ÊÇÈ«¹ú×îÔçµÄÒÀÍÐÓÚ´óÐÍ×ÛºÏÈý¼×Ò½ÔºµÄ´úл×éѧÑо¿ÖÐÐÄ£¬Ò²ÊÇÈ«¹úÏÖÓÐΨһһ¼Òҽѧ´úл×éѧ·½ÃæµÄ¹ú¼Ò¼¶¹ú¼ÊÁªºÏÑо¿ÖÐÐÄ¡£ÖÐÐÄÔÚ 2018 Äê±»¹ú¼Ò¿Æ¼¼²¿Åú׼Ϊ¹ú¼Ò¼¶¹ú¼Êҽѧ´úл×éѧ¹ú¼ÊÁªºÏÑо¿ÖÐÐÄ£¬Í¬Ê±Ò²±»ºþÄÏÊ¡¿Æ¼¼ÌüÈ϶¨ÎªºþÄÏÊ¡Ê×Åú¿Æ¼¼´´Ð¹ú¼ÊºÏ×÷»ùµØ¡£±¾ÖÐÐÄÓëÃÀ¹úµÂ¿ËÈøË¹´óѧ¡¢¹þ·ðҽѧԺ¡¢¿ÆÂÞÀ¶à´óѧ¡¢¼ÓÄôóÃÉÌØÀû¶û´óѧµÈ¹ú¼ÊÒ»Á÷Ñо¿»ú¹¹ÓÐ×ÅÎȶ¨µÄºÏ×÷¡£ ±¾ÖÐÐÄÏÖÓкËÐÄ¿ÆÑÐÍÅ¶Ó 8 ¸ö£¬¹ú¼Òº£Íâ¸ß²ã´ÎÈ˲ÅÒý½ø¼Æ»®×¨¼Ò 1 Ãû£¬¹ú¼Ò½ÜÇà 1 Ãû£¬¹ú¼ÒÓÅÇà 2 Ãû£¬²©Ê¿Éúµ¼Ê¦ 8 Ãû£¬Ë¶Ê¿Éúµ¼Ê¦ 8 Ãû£¬Áôѧ»Ø¹úÈËÔ± 50 ÓàÃû¡£ÖÐÐijÉÁ¢½ü3Äê¹²³Ðµ£Á˹ú¼Ò¼¶ÏîÄ¿ 11 ÏÆäÖйú¼Ò¿Æ¼¼²¿ÖصãÏîÄ¿ 3 Ï¹ú×ÔÈ»ÃæÉÏ»ù½ðÏîÄ¿4 Ï¹ú¼ÒÓÅÐãÇàÄê»ù½ðÏîÄ¿ 2 Ï¹ú×ÔÈ»ÇàÄê»ù½ðÏîÄ¿ 2 Ïî¡£ÔÚ Nat Med£¬Circulation£¬Cancer Cell£¬Cell Metabolism£¬Blood£¬Cir Res£¬Nat Comm£¬JCI µÈ¸ßˮƽÔÓÖ¾ÉÏ·¢±íÁË SCI ÊÕ¼ÂÛÎÄ 36ƪ£¬ÆäÖÐ IF>20 ·Ö 6 ƪ£¬IF>10 ·Ö 11 ƪ¡£ÅàÑøÁË¡°¹ú¼ÒÓÅÇࡱ2Ãû£¬¡°Ê¡½ÜÇࡱ2 Ãû£¬¡°Ê¡ÓÅÇࡱ1 Ãû£¬¡°ºþÏæÇàÄêÓ¢²Å¡±2 Ãû£¬ ¡°²©ºó´´ÐÂÈ˲š±1 Ãû£¬ÅàÑøË¶Ê¿Éú 12 Ãû£¬²©Ê¿Éú 21 Ãû¡£±¾ÖÐÐÄÓµÓпÆÑг¡µØ1100 ÓàÆ½Ã×£¬ÓµÓиßͨÁ¿´úл×éѧ¼ì²âƽ̨¡¢ÉúÎïÐÅÏ¢Óëר¼Ò·ÖÎöƽ̨¡¢ÖØ´ó¼²²¡×ª»¯Ñо¿Æ½Ì¨µÈÔÚÄڵġ°¶àλһÌ塱µÄ¹«¹²¼¼ÊõÑз¢¡¢Ó¦ÓÃÓëʾ·¶Æ½Ì¨¡£ ҽѧ´úл×éѧ¹ú¼ÊÁªºÏÑо¿ÖÐÐÄÖ¼ÔÚÀûÓôúл×éѧ¼¼Êõ½áºÏÆäËû×éѧ¶Ô¼²²¡µÄ·¢²¡»úÖÆ½øÐÐÉîÈëÑо¿£¬ÒÔÆÚ·¢ÏÖ¼²²¡µÄÔçÆÚÔ¤¾¯µÄÉúÎï±êÖ¾ÎÒÔ¼°¶ÔÂýÐÔ¼²²¡µÄÖÎÁƹý³Ì´úлÎïµÄ¼ì²â¶ø¶Ô¼²²¡½ø³Ì½øÐйÜÀí£¬½ø¶øÊµÏÖ¾«×¼Ò½ÁÆ¡£ ÒòÖÐÐÄ·¢Õ¹ÐèÒª£¬ÏÖ³ÏÆ¸»ùÓÚ´úл×éѧ¼¼ÊõµÄרְ¿ÆÑÐÈËÔ±¼°ÓÅÐãµÄ²©Ê¿ºóºÍ¼¼ÊõÔ±ÊýÃû£º Ò»¡¢ ÕÐÆ¸¸Úλ¼°ÒªÇó£º 1¡¢¶ÀÁ¢ PI £º2-3ÈË £¨1£©¾ßÓлòÕß½üÆÚ½«Òª»ñµÃ¹úÄÚÍâ¸ßˮƽ´óѧ»ò¿ÆÑÐÔºËù²©Ê¿Ñ§Î»»ò¾ß±¸²©Ê¿ºó¾Àú¡£¾ßÓÐÃâÒßѧ ¡¢·Ö×ÓÉúÎïѧ¡¢Ï¸°ûÉúÎïѧ¡¢ÉúÎﻯѧµÈÑо¿±³¾°¡£ £¨2£©ÕÆÎÕ´úл×éѧÑо¿µÄ¿ª·¢·½·¨ºÍÁ÷³Ì£¬¾ß±¸´úл×éѧÊý¾Ý·ÖÎö¼°´úлͨ··ÖÎöµÄÄÜÁ¦£¬ÊìÁ·ÕÆÎÕ¸÷ÀàÖÊÆ×¼¼ÊõÔÚ´úл×éѧµÄÓ¦Óᣠ£¨3£©¾ßÓжÀÁ¢¿ÆÑÐÄÜÁ¦£¬¿ÆÑÐËØÑøÁ¼ºÃ£¬¹¤×÷ÇÚ·Ṳ̈ʵ£¬¸»ÓÐÍŶӺÏ×÷ºÍ´´Ð¾«Éñ¡£ £¨4£©ÒÔµÚÒ»×÷ÕßÉí·ÝÔÚȨÍþÆÚ¿¯·¢±íSCIÑо¿ÂÛÎÄ£¬²¢¾ßÓнϺõÄÓ¢ÎÄд×÷ÄÜÁ¦¡£ £¨5£© ´ýÓöÃæÌ¸¡£ 2¡¢²©Ê¿ºó£º £¨1£© »ñµÃ£¨»ò¼´½«»ñµÃ£©ÃâÒßѧ¡¢·Ö×ÓÉúÎïѧ¡¢Ï¸°ûÉúÎïѧ¡¢ÉúÎﻯѧ»òҽѧÏà¹Ø×¨Òµ²©Ê¿Ñ§Î»£» £¨2£© ¾ßÓнÏÇ¿µÄÓ¢ÎĶÁдÄÜÁ¦£¬ÊìÁ·ÔĶÁÓ¢ÎÄÎÄÏ×£» £¨3£© ¾ßÓжÀÁ¢Ñо¿¹¤×÷ÄÜÁ¦ºÍºÏ×÷¾«Éñ£¬Ë¼Ïë»îÔ¾£¬ÀÖÓÚ½»Á÷£» £¨4£© ·¢±íIF²»µÍÓÚ5µÄÂÛÎÄÖÁÉÙһƪ£» £¨5£© ´ýÓö20Íò/Äê¡£ 3¡¢¼¼ÊõÔ±£º 2ÈË £¨1£©¾ßÓÐÉúÎﻯѧ¡¢Óлú»¯Ñ§¡¢ÎÞ»ú»¯Ñ§¡¢·ÖÎö»¯Ñ§¡¢Ï¸°ûÉúÎïѧ¡¢·Ö×ÓÉúÎïѧ¡¢Ò©Îï·ÖÎö¡¢ÒÇÆ÷·ÖÎöÏà¹ØÑо¿±³¾°£» £¨2£©±ØÐë¾ßÓÐ˶ʿ¼°ÒÔÉÏѧλ£» £¨3£©¾ßÓÐÖÊÆ×É«Æ×²Ù×÷¡¢·ÖÎö¼¼Êõ¾ÑéÕßÓÅÏÈ¿¼ÂÇ¡£ £¨4£©×÷ÎªÏæÑÅÒ½ÔºÕýʽԱ¹¤ÈëÖ°¡£ÏæÑÅÒ½ÔºÌṩÓоºÕùÁ¦µÄн³êºÍ¸£Àû¡£ ¶þ¡¢Ö°Òµ·¢Õ¹ °´ÕÕÖÐÄÏ´óѧºÍÏæÑÅÒ½ÔºÑо¿ÏµÁеĽúÉý¹æ¶¨£¬ÌṩÓÐǰ¾°µÄÖ°Òµ·¢Õ¹¿Õ¼ä¡£ Èý¡¢Ó¦Æ¸·½Ê½ ͨ¹ýµç×ÓÓʼþÌá½»ÉêÇ뱨¸æ¡¢¸öÈ˼òÀú¼°Ïà¹Ø¸½¼þÖ¤Ã÷²ÄÁÏ£¬×ÅÖØÂÛÊö´úл×éѧÏà¹ØµÄ¿ÆÑоÀúºÍ¸öÈË·¢Õ¹¹æ»®£¬²¢×¢Ã÷¿Éµ½¸Úʱ¼ä¡£ ÁªÏµÈË£ºÏÄÀÏʦ£ºxz888666999@163.com, µç»°£º15874869542 ¸½£ºÖÐÐĽüÆÚSCI ÊÕ¼ÂÛÎÄ 33 ƪ£¬ÆäÖйú¼ÊºÏ×÷ÂÛÎÄ 11 ƪ£¬IF>20 ·Ö 3 ƪ£¬IF>10 ·Ö 11 ƪ¡£ 1. Liu H#*, Kuang X#, Zhang Y, Ye Y, Li J, Liang L, Xie Z, Weng L,Guo J, Li H, Ma F, Chen X, Zhao S, Su J, Yang N, Fang F, Xie Y, TaoJ, Zhang J, Chen M, Peng C,Sun L, Zhang X, Liu J,Han L, Xu X,Hung MC, Chen X*.ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating theATF3-PD-L1 Axis. Cancer Cell. 2020;37:324-339.£¨IF:31.743) 2. Xiao YZ#, Yang M#, Xiao Y#, Guo Q, Huang Y, Li C, Cai D*, LuoXH*. Reducing Hypothalamic Stem Cell Senescence Protects against Aging-Associated Physiological Decline. Cell Metab. 2020 Mar3;31(3):534-548.e5. £¨IF: 27.287) 3. Li C, Xiao Y, Sun Y, He W, Liu L, Su T, Sun X, Guo Q, Huang Y,Yang M, Liu G, Luo XH *, Senescent immune cells release grancalcinto promote skeletal aging [J]. Cell metabolism.2021 Oct5;33(10):1957-1973.£¨IF: 27.287) 4. Xie T, Chen C, Peng Z, Brown BC, Reisz JA, Xu P, Zhou Z, Song A,Zhang Y, Bogdanov MV, Kellems RE, D\'Alessandro A, Zhang W,Xia Y: Erythrocyte Metabolic Reprogramming by Sphingosine 1-Phosphate in Chronic Kidney Disease and Therapies. Circ Res 2020,127:360-75 £¨IF: 17.367) 5. Li H, Kuang X, Liang L, Ye Y, Zhang Y, Li J, Ma F, Tao J, Lei G, ZhaoS, Su J, Yang N, Peng C, Xu X, Hung MC, Han L*, Liu H*, Liu J*and Chen X*. The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD-L1. Adv Sci (Weinh) 2021; 8:2001596 £¨IF:16.806) 6. Mingzhu Yin,Ying Guo,Rui Hu, Wesley L Cai, Yao Li, Shiyao Pei,Hongyin Sun, Cong Peng, Jiali Li, Rui Ye, Qiaohong Yang, Nenghui£¬Wang, Yongguang Tao, Xiang Chen, Qin Yan. Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. Nat Commun.2020Apr 14;11(1):1833. £¨IF: 14.919£© 7. Ye Y, Jing Y, Li L, Mills G. B, Diao L*, Liu H*,Han L*.Sex-associated molecular differences for cancer immunotherapy. Nature Communications. 2020;11(1):1779 £¨IF: 14.919£© 8. Jing Y#, Zhang Y#, Wang J#, Li K#, Chen X, Heng J, Gao Q, Ye Y,Zhang Z, Liu Y, Lou Y, Lin SH, Diao L, Liu H*, Chen X*, Mills GB*and Han L*. Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. J Natl Cancer Inst 2021£¨IF: 11.57) 9. Du JK, Yu Q, Liu YJ, Du SF, Huang LY, Xu DH, Ni X, Zhu XY. Anovel role of kallikrein-related peptidase 8 in the pathogenesis of diabetic cardiac fibrosis. Theranostics. 2021 Feb 20;11(9):4207-4231.doi:7150/thno.48530. eCollection 2021.PMID: 33754057 Free PMC article. (IF: 11.556£© 10. Ye Y#, Kuang X#, Xie Z#, Liang L, Zhang Z, Zhang Y, Ma F, Gao Q, Chang R, Lee HH, Zhao S, Su J, Li H, Peng J, Chen H, Yin M, Peng C, Yang N, Wang J, Liu J, Liu H*, Han L*, Chen X*. Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1. Genome Med. 2020 Sep 28;12(1):83. £¨IF:11.117£© 11. Peng Z, Luo R, Xie T, Zhang W, Liu H, Wang W, Tao L, Kellems RE, Xia Y: Erythrocyte Adenosine A2B Receptor-Mediated AMPK Activation: A Missing Component Counteracting CKD by Promoting Oxygen Delivery. J Am Soc Nephrol 2019, 30:1413-24.£¨IF:10.121)[ À´×Ô°æ¿éȺ ºþÄÏ ] |
» ±¾Ìû¸½¼þ×ÊÔ´Áбí
-
»¶Ó¼à¶½ºÍ·´À¡£ºÐ¡Ä¾³æ½öÌṩ½»Á÷ƽ̨£¬²»¶Ô¸ÃÄÚÈݸºÔð¡£
±¾ÄÚÈÝÓÉÓû§×ÔÖ÷·¢²¼£¬Èç¹ûÆäÄÚÈÝÉæ¼°µ½ÖªÊ¶²úȨÎÊÌ⣬ÆäÔðÈÎÔÚÓÚÓû§±¾ÈË£¬Èç¶Ô°æÈ¨ÓÐÒìÒ飬ÇëÁªÏµÓÊÏ䣺xiaomuchong@tal.com - ¸½¼þ 1 : ÖÐÄÏ´óÑ§ÏæÑÅÒ½ÔºÕÐÆ¸×¨Ö°¿ÆÑÐÈËÔ±.pdf
2022-02-17 15:44:25, 292.95 K
» ²ÂÄãϲ»¶
Î÷ÄϽ»Í¨´óѧ¹ú¼Ò¼¶È˲ÅÍŶÓ2026Ä격ʿÑо¿ÉúÕÐÉú£¨¿¼ºËÖÆ£©¡ª»úе¡¢²ÄÁÏ¡¢Á¦Ñ§·½Ïò
ÒѾÓÐ3È˻ظ´
¾ÈÃüÌû
ÒѾÓÐ6È˻ظ´
´æ¿î400Íò¿ÉÒÔÔÚѧУÀïÌÉÆ½Âð
ÒѾÓÐ37È˻ظ´
Ó¢ÎÄ×ÛÊöÊÇ·ñÐèÒªÈóÉ«¼°²éÖØ
ÒѾÓÐ5È˻ظ´
ÏÞÏî¹æ¶¨
ÒѾÓÐ5È˻ظ´
ΪʲônbsÉÏäå ûÓвúÎïµã³öÏÖÄØ
ÒѾÓÐ9È˻ظ´
Õв©Ê¿
ÒѾÓÐ3È˻ظ´
×îʧÍûµÄÒ»Äê
ÒѾÓÐ18È˻ظ´













»Ø¸´´ËÂ¥